Other studies also demonstrated niraparib’s promising clinical activity as neoadjuvant treatment for localized HER2[−], gBRCAm breast cancer and in triple-negative breast cancer, irrespective of gBRCAm status [23,24]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.